Aclarion, a healthcare technology company specializing in chronic low back pain treatments, is facing significant liquidity challenges and going concern issues. The company is actively pursuing additional financing options, including equity offerings and convertible preferred stock issuances, to address these concerns.Aclarion's core product, NOCISCAN, utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize surgical outcomes for discogenic low back pain patients. A clinical study demonstrated 97% patient improvement when all NOCISCAN-identified painful discs were treated surgically, compared to 54% when not treated. The company received Category III CPT codes in 2021 for reimbursement processes.Despite financial challenges, Aclarion has made progress in its commercialization efforts. The company completed an IPO in April 2022, raising $8.6 million, and entered an equity line agreement with White Lion Capital in October 2023 for up to $10 million. In November 2024, Aclarion issued 560,915 shares to White Lion as commitment shares, with recent securities issuances made under Section 3(a)(9) or 4(a)(2) of the Securities Act and Regulation D.

Aclarion, a healthcare technology company specializing in chronic low back pain treatments, is facing significant liquidity challenges and going concern issues. The company is actively pursuing additional financing options, including equity offerings and convertible preferred stock issuances, to address these concerns.Aclarion's core product, NOCISCAN, utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize surgical outcomes for discogenic low back pain patients. A clinical study demonstrated 97% patient improvement when all NOCISCAN-identified painful discs were treated surgically, compared to 54% when not treated. The company received Category III CPT codes in 2021 for reimbursement processes.Despite financial challenges, Aclarion has made progress in its commercialization efforts. The company completed an IPO in April 2022, raising $8.6 million, and entered an equity line agreement with White Lion Capital in October 2023 for up to $10 million. In November 2024, Aclarion issued 560,915 shares to White Lion as commitment shares, with recent securities issuances made under Section 3(a)(9) or 4(a)(2) of the Securities Act and Regulation D.